High dose inhaled fluticasone propionate improves FEV1 and results in reduction of oral glucocorticoid dose in glucocorticoid-dependent children with severe asthma.

S. A. McMurtry; S. R. Nimmagadda

High dose inhaled fluticasone propionate improves FEV1 and results in reduction of oral glucocorticoid dose in glucocorticoid-dependent children with severe asthma.

S. A. McMurtry^*, S. R. Nimmagadda

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

A retrospective chart review was performed on eight pediatric patients with glucocorticoid (GC)-dependent asthma who had been switched to fluticasone propionate (FP). A significant increase was noted in average forced expiratory volume in 1 second (FEV1) and forced expiratory flow 25-75% (FEF25-75) at 6 and 12 months. Significant reductions were noted in the oral GC dose at 6 and 12 months with a reduction at 12 months of almost 16.5 mg/day or 65% of the initial oral GC dose. This study suggests that high-dose FP use in children with oral GC-dependent asthma has oral GC sparing effects while improving FEV1 and FEF25-75.

Original language	English (US)
Pages (from-to)	373-376
Number of pages	4
Journal	Allergy and asthma proceedings : the official journal of regional and state allergy societies
Volume	22
Issue number	6
State	Published - 2001

ASJC Scopus subject areas

Immunology and Allergy
Pulmonary and Respiratory Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{1a9fdf6100484a4f97b54d105a1befa0,

title = "High dose inhaled fluticasone propionate improves FEV1 and results in reduction of oral glucocorticoid dose in glucocorticoid-dependent children with severe asthma.",

abstract = "A retrospective chart review was performed on eight pediatric patients with glucocorticoid (GC)-dependent asthma who had been switched to fluticasone propionate (FP). A significant increase was noted in average forced expiratory volume in 1 second (FEV1) and forced expiratory flow 25-75% (FEF25-75) at 6 and 12 months. Significant reductions were noted in the oral GC dose at 6 and 12 months with a reduction at 12 months of almost 16.5 mg/day or 65% of the initial oral GC dose. This study suggests that high-dose FP use in children with oral GC-dependent asthma has oral GC sparing effects while improving FEV1 and FEF25-75.",

author = "McMurtry, {S. A.} and Nimmagadda, {S. R.}",

year = "2001",

language = "English (US)",

volume = "22",

pages = "373--376",

journal = "Allergy and asthma proceedings : the official journal of regional and state allergy societies",

issn = "1088-5412",

publisher = "OceanSide Publications Inc.",

number = "6",

}

High dose inhaled fluticasone propionate improves FEV1 and results in reduction of oral glucocorticoid dose in glucocorticoid-dependent children with severe asthma. / McMurtry, S. A.; Nimmagadda, S. R.
In: Allergy and asthma proceedings : the official journal of regional and state allergy societies, Vol. 22, No. 6, 2001, p. 373-376.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - High dose inhaled fluticasone propionate improves FEV1 and results in reduction of oral glucocorticoid dose in glucocorticoid-dependent children with severe asthma.

AU - McMurtry, S. A.

AU - Nimmagadda, S. R.

PY - 2001

Y1 - 2001

N2 - A retrospective chart review was performed on eight pediatric patients with glucocorticoid (GC)-dependent asthma who had been switched to fluticasone propionate (FP). A significant increase was noted in average forced expiratory volume in 1 second (FEV1) and forced expiratory flow 25-75% (FEF25-75) at 6 and 12 months. Significant reductions were noted in the oral GC dose at 6 and 12 months with a reduction at 12 months of almost 16.5 mg/day or 65% of the initial oral GC dose. This study suggests that high-dose FP use in children with oral GC-dependent asthma has oral GC sparing effects while improving FEV1 and FEF25-75.

AB - A retrospective chart review was performed on eight pediatric patients with glucocorticoid (GC)-dependent asthma who had been switched to fluticasone propionate (FP). A significant increase was noted in average forced expiratory volume in 1 second (FEV1) and forced expiratory flow 25-75% (FEF25-75) at 6 and 12 months. Significant reductions were noted in the oral GC dose at 6 and 12 months with a reduction at 12 months of almost 16.5 mg/day or 65% of the initial oral GC dose. This study suggests that high-dose FP use in children with oral GC-dependent asthma has oral GC sparing effects while improving FEV1 and FEF25-75.

UR - http://www.scopus.com/inward/record.url?scp=18744429575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18744429575&partnerID=8YFLogxK

M3 - Article

C2 - 11775395

AN - SCOPUS:18744429575

SN - 1088-5412

VL - 22

SP - 373

EP - 376

JO - Allergy and asthma proceedings : the official journal of regional and state allergy societies

JF - Allergy and asthma proceedings : the official journal of regional and state allergy societies

IS - 6

ER -

High dose inhaled fluticasone propionate improves FEV1 and results in reduction of oral glucocorticoid dose in glucocorticoid-dependent children with severe asthma.

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this